Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioSample Inc.

This article was originally published in Start Up

Executive Summary

In the course of validating disease targets or developing drugs, researchers need tissue samples from patients with specific types of diseases as well as from healthy patients.BioSample Inc., has an internet-enabled biological material procurement solution to the pharmaceutical/biotech community.

You may also be interested in...



Biorepositories

Despite the in silico research ideals of many genomicists, no one has yet found a way around the basic requirement for using human tissue in gene expression studies-a broad array of it, well characterized, from healthy and diseased patients, and from world populations at large. That's why start-ups, drug discovery firms and others are creating a new resource: biorepositories--banks of tissue samples and data to serve the diagnostic, pharmaceutical and tissue engineering industries. As providers of services and products to research-based companies, these companies believe they are operating in a market that ranges from $500 million to $5 billion.

As Dot-coms Reel, Broadlane Steps Forward

While Ventro Corp. announces the closing of two of its B2B e-commerce businesses, its Broadlane business announces a major group purchasing agreement with Kaiser Permanente.

E-Health's Second Mover Advantage

The revolution that the Internet is bringing to hospital supply is really two revolutions, one transaction-oriented, the other information-based. MedAssets hopes to capitalize on opportunities in the transaction-based realm by, in effect, applying Internet technology to two relatively traditional service businesses, group purchasing, and capital equipment refurbishing and resale. MedChannel, by contrast, is trying to create an infochannel that promotes wide efficiencies across a broadly defined supply chain, from OEM to end user. Both companies face a challenge: that of coming late to a B2B e-commerce market that is evolving rapidly. Their hope: a kind of "Second Mover Advantage", under which the early B2B leaders open doors to customers that both companies can more easily walk through.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC090436

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel